Taken together, these results indicate that in AML, SYK inhibition reduces the activity of its downstream pathways (p-ERK1/2, p-STAT5, and MYC), induces differentiation, and reduces clonogenic potential and viability of AML cells. This evidence concerns the gene MAPK3 and acute myeloid leukemia.